Advanced Genetic Approaches in Discovery and Characterization of Genes Involved With Osteoporosis in Mouse and Human

Jinbo Yuan¹, Jennifer Tickner¹, Benjamin H. Mullin¹-², Jinmin Zhao³*, Zhiyu Zeng⁴, Grant Morahan⁵ and Jiake Xu¹*

¹ School of Biomedical Sciences, The University of Western Australia, Perth, WA, Australia, ² Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia, ³ Research Centre for Regenerative Medicine, Guangxi Medical University, Nanning, China, ⁴ The First Affiliated Hospital of Guangxi Medical University, Nanning, China, ⁵ Centre for Diabetes Research, Harry Perkins Institute of Medical Research, The University of Western Australia, Perth, WA, Australia

Osteoporosis is a complex condition with contributions from, and interactions between, multiple genetic loci and environmental factors. This review summarizes key advances in the application of genetic approaches for the identification of osteoporosis susceptibility genes. Genome-wide linkage analysis (GWLA) is the classical approach for identification of genes that cause monogenic diseases; however, it has shown limited success for complex diseases like osteoporosis. In contrast, genome-wide association studies (GWAS) have successfully identified over 200 osteoporosis susceptibility loci with genome-wide significance, and have provided most of the candidate genes identified to date. Phenome-wide association studies (PheWAS) apply a phenotype-to-genotype approach which can be used to complement GWAS. PheWAS is capable of characterizing the association between osteoporosis and uncommon and rare genetic variants. Another alternative approach, whole genome sequencing (WGS), will enable the discovery of uncommon and rare genetic variants in osteoporosis. Meta-analysis with increasing statistical power can offer greater confidence in gene searching through the analysis of combined results across genetic studies. Recently, new approaches to gene discovery include animal phenotype based models such as the Collaborative Cross and ENU mutagenesis. Site-directed mutagenesis and genome editing tools such as CRISPR/Cas9, TALENs and ZNFs have been used in functional analysis of candidate genes in vitro and in vivo. These resources are revolutionizing the identification of osteoporosis susceptibility genes through the use of genetically defined inbred mouse libraries, which are screened for bone phenotypes that are then correlated with known genetic variation. Identification of osteoporosis-related susceptibility genes by genetic approaches enables further characterization of gene function in animal models, with the ultimate aim being the identification of novel therapeutic targets for osteoporosis.

Keywords: osteoporosis, GWLA, GWAS, PheWAS, WGS, collaborative cross, genome editing
INTRODUCTION

Osteoporosis is a common skeletal condition that is characterized by low bone mass, abnormal mineralization, increased bone turnover rate and fragility (Burr, 2002). The diagnosis of osteoporosis relies on the measurement of bone mineral density (BMD) of the axial skeleton using dual energy x-ray absorptiometry (DXA) (Adler et al., 2000). Clinically, osteoporosis tends to remain undiagnosed until fracture has occurred (Unnanuntana et al., 2010). It is a highly prevalent condition affecting more women than men. Approximately 40% of Caucasian postmenopausal women are estimated to be affected by osteoporosis. Furthermore, the lifetime fracture risk for an osteoporotic individual is estimated to be as high as 40%, with fractures most commonly occurring in the spine, hip, or wrist (Burge et al., 2007; Unnanuntana et al., 2010).

The high risk of developing osteoporosis in specific populations suggests an underlying role of bone genetics in the development of this condition. Indeed, the genetic architecture of osteoporosis is typically complex, with contributions from multiple genetic loci and interactions with various environmental factors (Wade, 2001). With regards to the genetic aspect, even though more than 200 loci have been confidently linked to this complex condition, the genetic architecture, the number of susceptibility loci, the distribution of their allele frequencies, and the size of their effects, remains largely unknown (Ralston, 2010). For most osteoporosis phenotypes, the majority of these genetic loci present small effects, given that few genes cause significant phenotypes in rare bone diseases, such as osteogenesis imperfecta and osteopetrosis, which follow Mendelian inheritance patterns and are caused by high penetrance mutations at a single locus (Rikhotso et al., 2008; Basel and Steiner, 2009).

Many osteoporosis-related traits such as BMD, bone loss, and osteoporotic fracture are highly heritable. BMD is considered to be a surrogate for osteoporosis and the strongest predictor of osteoporotic fractures (Black et al., 2018). A significant amount of the variance in peak BMD is genetically determined, with estimates ranging from 40 to 90% in various twin and family studies (Howard et al., 1998; Park et al., 2012; Hernandez-de Sosa et al., 2014). Twin studies have also revealed that genes account for 25–45% of the variation in age-related bone loss (Zhai et al., 2009; Mitchell and Yerges-Armstrong, 2011). Genetic factors also have a large contribution to fracture propensity. In the Framingham Heart Study (FHS) with a total of 4,134 cases of vertebral fracture, heritability was estimated to be up to 43% (Liu et al., 2012). The heritability of wrist and hip fractures was also estimated at 54 and 68% respectively, in peri-menopausal women (Andrew et al., 2005; Michaelsson et al., 2005).

Several methods have been widely used to identify osteoporosis-related genes. In this review, we will focus on the principles and the applications underlying these methods.
APPROACHES TO IDENTIFY THE GENETIC ARCHITECTURE OF OSTEOPOROSIS

Genome-Wide Linkage Analysis (GWLA)

Genome-wide linkage analysis (GWLA) is a well-established genetic approach for identifying disease-risk genetic loci by scanning genome-wide markers in pedigrees segregating a trait. This approach can be categorized into two forms, parametric linkage analysis and model-free linkage analysis. The former is of most use in identifying mutations causing inherited monogenic Mendelian human diseases. The fundamental basis of this approach is looking for the segregation of gene variants (also called alleles) in diseases following dominant or recessive inheritance patterns within a family (Ralston, 2010). It has been employed successfully in identifying the causative gene for several monogenic diseases (Peltonen and McKusick, 2001). The latter form is used for complex traits with unknown inheritance pattern. In general, GWLA has shown less capability in identifying loci that are more likely to harbor genes for the complex traits or diseases as compared to Mendelian diseases/traits.

In bone, several attempts at using GWLA to detect loci that regulate BMD have failed to achieve consistent results and only very limited replication of linkage peaks was found in different studies (Karasaki et al., 2002; Shen et al., 2004; Ralston et al., 2005; Hsu et al., 2007). In efforts to improve the statistical power for detecting responsible loci, several meta-analyses of GWLA have been performed but have yielded limited success. For example, a meta-analysis containing 11 genome-wide linkage studies (total of 3,097 families with 12,685 individuals) for BMD or osteoporosis found seven linkage loci across studies but failed to provide evidence at the genome-wide significance level for any locus (Lee et al., 2006). Another similar large-scale meta-analysis with 11,842 subjects also failed to detect any genome-wide significant linkage associations, even though replication of several quantitative trait loci (QTL) from individual studies was identified (Ioannidis et al., 2007). This reflects the limited application of linkage analysis in the detection of genes modestly regulating BMD. GWLA remains as a powerful tool in identifying genes for Mendelian diseases/trait. However, during the past decade, this primary method for gene discovery has been replaced by another approach, the genome-wide association study (GWAS), which also exploits the linkage disequilibrium among dense markers in large populations.

Candidate Gene Association Studies

Candidate gene studies were at the forefront of early efforts to identify osteoporosis susceptibility genes. The candidate gene approach focuses on assessing single nucleotide polymorphisms (SNPs) within genes that have a known role in a specific trait or disease. This approach has limited capability in gene discovery. Furthermore, it has been criticized on other aspects including lack of replication and lack of statistical power due to relatively small sample sizes (Wilkening et al., 2009; Patnala et al., 2013). Therefore, most of the results from candidate gene association studies should be interpreted with caution.

Approximately 200 candidate genes have been explored for their potential association with BMD or fracture in human populations (visit HuGE Navigator). A successful collaborative meta-analysis for osteoporosis candidate genes was performed using data from 19,195 subjects (including 14,277 women) from five Caucasian populations (Richards et al., 2009). Based on this study, researchers investigated 36,016 SNPs within 150 candidate gene loci and identified several SNPs from nine genes (ESR1, LRP4, LRP5, ITGAI, SOST, SPP1, TNFRSF11A, TNFRSF11B, and TNFSF11) as associated with BMD at either the femur neck or lumbar spine, with SNPs from four genes (LRP5, SOST, SPP1, and TNFRSF11A) significantly associated with fracture risk. The genetic effect sizes for BMD SNPs were also assessed, and results revealed no dominant allelic effects (Richards et al., 2009). Consequently, it was concluded that most genes selected for analysis in candidate gene studies for osteoporosis are likely not associated with bone phenotypes.

Genome-Wide Association Study

Genome-wide association study is hypothesis-free approach which appears to be more practical and effective than GWLA in the mapping of genetic loci associated with a complex disease or trait by scanning high-density markers distributed across the genome. It has greater statistical power than GWLA to identify common contributing genetic variants that do not follow Mendel’s laws of segregation (Hirschhorn and Daly, 2005). A typical GWAS includes several stages (Figure 2). The discovery stage focuses on identifying association between SNPs and traits in a large cohort with quantitative trait or case/control phenotype data. The second stage focuses on the replication of the most promising preliminary associations in an independent cohort. Meta-analysis of the discovery/replication cohorts can be applied to maximize statistical power at this point. The final stage focuses on the validation of the detected associations through pathway analyses, determination of mechanism or genetic manipulation in animal models. Currently, the genome-wide significance P-value threshold of $5 \times 10^{-8}$ is generally applied to identify significant associations (Hoggart et al., 2008); however, other less stringent thresholds have also been employed (e.g., $P \leq 5 \times 10^{-7}$) (Wellcome Trust Case Control Consortium, 2007).

The first recognized GWAS on bone phenotypes was published in 2007. In this study, 70,987 autosomal SNPs were evaluated in 1,141 patients (646 women and 465 men) against a range of phenotypes including BMD, broadband ultrasound attenuation (BUA), and fracture risk (Kiel et al., 2007). Even though several SNPs in genes such as MTHFR, ESR1, LRP5, VDR, and COL1A1 showed evidence of association with osteoporosis, none of these variants achieved genome-wide significance due to the relatively small sample size and low genetic coverage. Subsequent studies published simultaneously in 2008 identified five loci that reached genome-wide significance with BMD, including OPG, LRP5, ESR1, RANKL, and ZBTB40 (Richards et al., 2008; Styrkarsdottir et al., 2008). deCODE Genetics identified another four genome-wide significant loci near or at
FIGURE 2 | Workflow of GWAS. A typical GWAS includes three stages: discovery, replication and validation. The discovery stage focuses on identifying associations between SNPs and traits based on a large cohort with either quantitative trait or case/control phenotype data. The second stage focuses on the replication of preliminary associations in an independent cohort. Meta-analysis can be applied to increase the statistical power of individual GWAS at this stage. The final stage focuses on the validation of the detected associations through pathway analyses, determination of mechanism or genetic manipulation in animal models.
TABLE 1 | Genes with genome-wide significant evidence for association with BMD and osteoporosis.

| Study                  | Type of study | Number of subjects | Key genes identified                                                                 |
|------------------------|---------------|--------------------|---------------------------------------------------------------------------------------|
| Kiel et al., 2007      | GWAS          | 1,141              | “none”                                                                                |
| Richards et al., 2008  | GWAS          | 8,557              | TNFRSF11B (OPG), LRP5                                                                  |
| Strykarsdottir et al., 2008 | GWAS          | 13,786             | OPG, TNFRSF11 (RANKL), ESR1, ZBTB40                                                  |
| Timpson et al., 2009   | GWAS          | 5,275 (children)   | SP7                                                                                   |
| Strykarsdottir et al., 2009 | GWAS          | 15,375             | “None”                                                                                |
| Rivadeneira et al., 2009 | GWAS, GWAS meta-analysis | 19,196             | GPR177 (WLS), SPTBN1, CTNNB1, MEPE, MEF2C, STAR03NL, FLJ42280, LRP4, ARHGAP1, F2, DCCD5, SOX6, FOXL1, HDAC5, ORR1, ZBTB40, ESR1, TNFRSF11B, LRP5, SP7, TNFRSF11, TNFRSF11A |
| Xiong D.H. et al., 2009 | GWAS, GWAS meta-analysis | 9,828              | ADAMTS18, TGFB3                                                                       |
| Karasik et al., 2010   | GWAS          | 2,073              | “None”                                                                                |
| Guo et al., 2010       | GWAS          | 11,568             | ALDH7A1 (fracture)                                                                    |
| Kung et al., 2010      | GWAS, GWAS meta-analysis | 18,898             | JAG1                                                                                  |
| Hsu et al., 2010       | GWAS meta-analysis | 11,290             | RAP1A, TBC1D8, OSBPL1A, GPR177, SOX6, TNFRSF11B                                       |
| Koller et al., 2010    | GWAS          | 2,193              | “None”                                                                                |
| Duncan et al., 2011    | GWAS          | 21,798             | GALNT3, RSPO3                                                                        |
| Estrada et al., 2012   | GWAS meta-analysis | 186,338            | RERE, ZBTB40, WLS, SPTBN1, GALNT3, CTNNB1, MEPE, MEF2C, CDKAL1, C6orf97, TNDC3, STAR03NL, SLC25A13, C7orf58, WNT16, KXFR, TNFRSF11B, FUBP3, MPP7, MBL2, KCNMA1, SOX6, ARHGAP1, LRP5, SP7, HOXO6, AKAP11, RPS6KA5, AXIN1, SALL1, FOXL1, SMG6, C17orf53, SOX9, TNFRSF11A, GRAP1CH1, JAG1 |
| Zheng et al., 2012     | GWAS, GWAS meta-analysis | 5,672              | WNT16, TNFRSF11                                                                       |
| Medina-Gomez et al., 2012 | GWAS, GWAS meta-analysis | 13,712             | WNT16, FAM3C, C7orf88 (CPED1)                                                         |
| Paternoster et al., 2013 | GWAS meta-analysis | 10,452             | RANKL, LOC285735, OPG, ESR1, C6orf97, FMN2, GREM2                                    |
| Koller et al., 2013    | GWAS meta-analysis | 14,402             | WNT16, ESR1, C6orf97                                                                  |
| Zhang et al., 2014     | GWAS meta-analysis | 27,061             | SMO2C1, CLDN14, ZBTB40, GPR177, FGFR1, MEPE, MEF2C, C6orf97, ESR1, FLJ42280, SHFM1, FAM3C, WNT16, TNFRSF11B, SOX6, LRP5, AKAP11, FOXL1 |
| Moayyeri et al., 2014  | GWAS meta-analysis | 70,694             | TMEM135, ESR1, SPTBN1, RSPO3, WNT16, DKK1, GRAP1CH1                                   |
| Chesi et al., 2015     | GWAS          | 1,399 (children)   | CPED1, WNT16, FAM3C, MIR31HG, MTAP                                                  |
| Mulin et al., 2016     | GWAS meta-analysis | 6,696              | WLS                                                                                  |
| Mulin et al., 2017     | GWAS, GWAS meta-analysis | 16,627             | PPP1R3B, LOC387810, SEPT5                                                            |
| Kemp et al., 2017      | GWAS          | 142,487            | ACTR2D2, RERE, MTO1, SPP4, WNT4, ZBTB40, ARID1A, SF3A3, WLS, PKN2, WNT25B, TBX15, PRK1, DNM3, HHAT, C1orf140, FNN2, TMEM18, PPP1CB, SLC9a1, C2orf91, THADA, SPTBN1, ZNF938, INSG22, EN1, TANC1, FGFB2, CDK15, FZD7, KIAA2012, ICAL1, NGEF, MLPH, ATG7, RARB, SLUSD5, CTNNB1, ERC2, LEK1, LINC00880, IDU1A, FGFR1, IGF2BP7, SLC4A4, ARHGAP24, AFF1, DMP1, MEPE, SMARCAD1, OTUD4, ZNF827, DGFGC, CDH6, SLC1A3, DAB2, PLPP1, RASGRF2, CARMN, RREB1, CASC15, HLA-A, SUPT3H, GFRAL, BMP5, RSPO3, L3MBTL3, EYA4, ESR1, MEOX2, CREB5, AQP1, SFRP4, FAM133B, C7orf78, CPED1, WNT16, MPD2, RAPP, ABO, PLxdc2, MBL2, KCNMA1, SOX6, LRP4, LRP5, CADM1, WNT1, GPC6, BMP4, SMAD3, FTO, SMG6, SOST, TMEM92, AXIN2, TNFRSF11A, NFATC1, BMP2, JAG1, ERG, ITG8B, FAM9B |

BMD loci that reached genome-wide significance (GWAS; P < 5 x 10^-8).
Yuan et al. Approaches for Osteoporosis Genes Discovery

FIGURE 3 | Important genetic loci associated with BMD. There are key genes identified in GWAS for BMD at various skeletal sites: total hip, femoral neck, lumbar spine, wrist or radius, and heel.

(Rivadeneira et al., 2009; Estrada et al., 2012; Hsu and Kiel, 2012; Chesi et al., 2015). This phenomenon is not uncommon in GWAS due to the very strict genome-wide significance threshold resulting in possible false negatives. To interpret those inconsistent results between studies, as a rule of thumb, is suggested to consider a gene reaching genome-wide significance in any GWAS as “positive,” regardless of failure in achieving significance in other studies. Furthermore, statistical power can affect the outcome of GWAS. The larger the population size, the greater the power of the cohort to detect associations using the genome-wide threshold.

However, even if SNPs are identified as genome-wide significant, this phenotype-to-genotype approach often fails to establish clinically significant associations. Moreover, GWASs predominately identify common variants rather than uncommon or rare variants. Lastly, challenges exist in the characterization of the majority of GWAS SNPs which are intergenic. Establishing the function of these intergenic SNPs requires further or alternative strategies such as expression quantitative trait locus (eQTL) studies (Mullin et al., 2018, 2019), functional studies in animals, or the phenome-wide association study (PheWAS).

Phenome-Wide Association Study (PheWAS)

PheWAS can be viewed as a reverse version of GWAS. Unlike GWAS, which applies a phenotype-to-genotype approach, PheWAS starts with a given single genetic variant to test for association with a wide range of human clinical phenotypes, the phenotype (Figure 4). This genotype-to-phenotype strategy is a novel approach, with the first PheWAS as a proof-of-concept study published in 2010. This study demonstrated the feasibility of PheWAS to discover significant gene-disease associations (Denny et al., 2010). This technique is of particular usefulness in the re-discovery of known key genetic associations linked to immunological diseases (Hebbring, 2014). It also has the capacity to identify association between SNPs and bone phenotypes. For example, Wang et al. (2016) successfully identified a missense variant in collagen 6A5 (Col6a5) as associated with BMD, along with other numerous genotype-phenotype associations in a cohort of BXD recombinant inbred strains (n = 150), and a European human population (n = 29,722). PheWAS has a potential advantage over GWAS in being able to identify uncommon or rare variants responsible for bone phenotypes. However, this technique is significantly less efficient than GWAS in the discovery of genetic variants associated with bone diseases/conditions. Rather, PheWAS may be used as a complementary approach to either further investigate the associations between a genome-wide significant BMD-relevant SNP and clinical phenotypes beyond the skeletal system, or re-discover the association between a non-GWAS-significant BMD SNP and a wide spectrum of phenotypes including osteoporosis, osteopetrosis and osteoarthritis. Therefore, PheWAS has the potential to unlock novel genetic loci or variants that would not be possibly revealed by other genetic approaches.
FIGURE 4 | Workflow of PheWAS. The PheWAS can start with animal or directly with human cohorts. A typical approach is to identify high-impact variants within the RI strains, then correlate these variants with the mouse phenome, followed by validation of candidate variants in human cohorts.

Whole Genome Sequencing (WGS)

Whole genome sequencing (WGS), also known as complete genome sequencing, is a technique that is capable of generating a complete set of DNA sequence variants rather than relying on the patterns of linkage disequilibrium for markers. Conventional sequencing of the whole genome of animal or human subjects is time-consuming; however, large scale WGS can be achieved using next-generation sequencing (NGS) platforms such as Ion Torrent’s PGM, Pacific Biosciences’ RS and the Illumina MiSeq (Quail et al., 2012). These sequencing techniques have been applied for complete characterization of candidate genes identified from GWAS.

Unlike GWAS, which relies on testing common variants (MAF ≥ 5%), WGS aims to assess the role of low frequency (MAF 1–5%) and rare (MAF ≤ 1%) genetic variation. A recent sequencing-based study, which included 4,931 Icelandic subjects with low BMD, along with population-based controls (total n = 69,034), identified a rare nonsense variant (c.376C>T) within the leucine-rich-repeat-containing G-protein-coupled receptor 4 (LGR4) locus as associated with low BMD and high fracture risks (Styrkarsdottir et al., 2013). Another study incorporating WGS, whole-exome sequencing and genotype imputation identified two novel low-frequency non-coding variants associated with BMD near EN1 and WNT16 in a total of 53,236 subjects (Zheng et al., 2015). The SNP (2q14.2, rs11692564[T], MAF = 1.7%) near EN1 was found to have a larger effect size than previously reported common BMD variants for the lumbar spine, and was also associated with a low fracture risk (Estrada et al., 2012). Conditional knockout En1Cre/flx mice showed reduced bone mass, probably due to high bone turnover. Another SNP (rs148771817[T], MAF = 1.1%) near WNT16 also showed significant association with BMD, adding evidence that this gene has large effects on osteoporosis across skeletal sites. Overall, these studies provide rationale for WGS to investigate the genetic composition of complex traits/disease in the global population. With dramatic reduction in the cost of WGS, this approach are expected to identify uncommon or rare variants which are likely missed by GWLA or GWAS. It could be applied for individual genome sequencing, which can guide the practice of personalized medicine.

Animal Models

Animal models have been widely used to investigate the contribution of specific genes to the determination of bone mass and microarchitecture. In comparison with human populations, animal models offer several advantages, including a greater ability in environmental control, fast breeding rates, reproducible and easier access to trait-relevant tissues, the ability to easily monitor age-related phenotypes, and most importantly, genetic manipulations through gene knockout and knockin (allele swaps). Genetic manipulations through gene knockout and targeted mutations are of most importance for these animals models, and have been used to further evaluate the impact of loss-of-function or gain-of-function of osteoporosis susceptibility genes (e.g., EN1 and SOST) identified from other genetic approaches or in human populations (Zheng et al., 2015; Sebastian and Loots, 2017).

Of those animals utilized in the past, mice and rats have been used far more widely than other animals such as rabbits, dogs, sheep or non-human primates (Jee and Yao, 2001; Shmookler Reis and Ebert, 2003). The mouse and human share high degree of similarity, with over 17,000 mouse protein coding genes have
a known human homolog\(^1\). Such similarity provides a rationale that using mouse models to resemble genetic studies for humans, and mouse models have been considerably applied in studies of the genetic inheritance of bone mass, geometry and strength (Ishimori et al., 2006; Xiong Q. et al., 2009; Ackert-Bicknell et al., 2010; Jepsen et al., 2010; Smith et al., 2014). Hence for genetic analysis the mouse model is most efficacious, in particular for the study of common human skeletal diseases such as osteoporosis. However, we still need to be aware of that many findings in mice cannot resemble the gene-phenotype association in humans. Caution in translating such murine results in human populations is required.

The Collaborative Cross (CC)

The CC is essentially a form of GWAS in mice. It is a large-scale community-based project for developing recombinant inbred (RI) strains from eight fully genotyped parental strains that were carefully selected to catch nearly 90% of genetic variance in the mouse genome (Churchill et al., 2004; Morahan et al., 2008). The RI strains are generated by mating pairs of sibling F2 mice until fully inbred for each line, which requires 20 generations or more (Churchill et al., 2004). Because the CC strains are RI, genotyping of the mice are generally not required as their genotypes have been computationally resembled and are already available on public databases. The design of GWAS in CC mice fundamentally differs from the design of GWAS in humans (Figure 5). Analyzing traits of CC strains and searching for associations between phenotypes and genotypes are key steps in the study, followed by validation of genes of interest. The CC mice offer a novel avenue to explore the genetic architecture of complex traits such as osteoporosis.

Collaborative cross mice breeding is still in progress in order to achieve at least 1,000 independent lines and its application in genetic research is in its infancy. Generation of the targeted numbers of independent lines is unlikely to be achieved within the next decade due to limited ongoing funding and increased cost of animal handling and housing. Applications of CC mice over the past decade mainly focused on pre-CC mice, which are not fully inbred, and a wide range of phenotypes have been found in these studies (Bottomly et al., 2012; Phillippi et al., 2014; Ferguson et al., 2015). Inbred CC mice used in combination with other mouse models (e.g., transgenic) have also been applied, for example, in the identification of a mutation in the Cd40 gene that accelerates congenital naevus growth (Chitsazan et al., 2016). The function of this gene has now been further investigated using knockout mouse models (Chitsazan et al., 2017). Simulations of the power and precision of genetic mapping with the CC population demonstrated superior performance relative to traditional or alternative strategies (Broman, 2005; Valdar et al., 2006; Ram et al., 2014; Ram and Morahan, 2017).

So far, there is only one published study that analyzed genes for bone microarchitecture using a cohort of CC mice (Levy et al., 2015). This study utilized 160 mice across 31 lines to perform genome-wide haplotype mapping across 77,808 SNPs, and analyzed four trabecular traits (Levy et al., 2015). Haplotype association mapping revealed six QTLs, and numerous candidate genes such as Oxt and Avp. Oxt that encodes a precursor of oxytocin, and Avp encoding arginine-vasopressin appear to be promising since their proteins have shown a direct skeletal

---

\(^1\)http://www.informatics.jax.org/homology.shtml

![FIGURE 5](image-url)

**FIGURE 5** Workflow of the collaborative cross mice screening. The CC study starts with searching for associations among strains and identification of candidate genes within the identified locus, followed by validation of those candidate genes for association with the phenotype. Correlation with human datasets add confidence for the SNPs/gene. Validation can be done by gene expression, pathway analysis and looking at the functions of selected genes through transgenic or knockout mouse models.
effect in other studies (Tamma et al., 2009; Sun et al., 2016). These findings provide a proof-of-concept that the CC is a powerful tool in the identification of genes that are responsible for complex traits or diseases. However, this study had several limitations such as small sample size (average of five mice per line), narrow age range (10–13 weeks), limited number of strains and limited parameters/trait. Such limitations may lead to a sub-optimal estimation of candidate genes responsible for bone microarchitecture. Further studies with a large scale of CC mice, therefore, are required.

**Mutagenesis and Characterization of Candidate Genes**

Mutagenesis can be achieved either randomly or in a more controlled or direct way. Random mutagenesis is usually induced using chemicals such as N-ethyl-N-nitrosourea (ENU), which has proven to be an efficient way for generating mutations in phenotype-driven screening (Nelms and Goodnow, 2001; Stottmann and Beier, 2010). The high-throughput screening technique has previously unveiled numerous novel mutations that cause dysfunction of tissues and organs (Nelms and Goodnow, 2001). More recently, screening mice for mutations that affect bone phenotypes has been carried out. The screen involves assessing mouse bone density and skeletal structure in ENU-induced mutant mice (Mohan et al., 2007; Chen et al., 2014). This phenotype-driven approach enables a unique tool for studying genes regulating bone biology, including choline kinase beta (Chkb) (Kular et al., 2015), Morc3 (Jadhav et al., 2016), and Tnfsf11 (Rankl) (Douni et al., 2012).

Site-directed mutagenesis is another approach that utilizes plasmids within *Escherichia coli* (Shen, 2002). This approach was developed based on a battery of techniques including polymerase chain reaction (PCR), DpnI digestion, ligation and plasmid transformation (Shen, 2002). It usually yields mutations in over 50% of the desired mutated proteins, and allows study of the relationship between the gene sequence and its function. In the past, this technique was primarily targeted at one specific site using one set of primers. Recently, this technique has been modified, allowing site-directed mutagenesis at several sites within the plasmids without primers and ligation (Tian et al., 2010). Such advances significantly simplify the standard procedure in a more cost-effective way. So far, site-directed mutagenesis has been predominantly used in functional analysis of genes *in vitro*, including bone-related molecules such as bone sialoprotein (Harris et al., 2000), and neural epidermal growth factor-like (NEL)-like 1 (Takahashi et al., 2015). This technique provides an avenue to gene characterization *in vitro*, which is useful in linking a gene to a bone phenotype after gene screening by other approaches.

More recently, the field of genome editing has gained popularity and research interest. This technique encompasses a group of biotechnology tools (engineered sequence-specific nucleases) that allow researchers to modify the gene of interest. These tools such as zinc-finger nucleases (ZFNs) (Carroll, 2011), transcription activator-like effector nucleases (TALENs) (Joung and Sander, 2013), and CRISPR/Cas9 (Ran et al., 2013), have been successfully applied to modify genomes with unprecedented efficiency and precision. ZFNs and TALENs can cleave sequences non-specifically, while the CRISPR/Cas9 system can cut the sequences more precisely using the guide DNA. With the commercial availability of thousands of customized guide DNA sequences, CRISPR/Cas9 is considered the most promising tool in gene editing among these nucleases (Williams and Warman, 2017; Cui et al., 2018). CRISPR/Cas9 has been used successfully to create animal models through microinjecting

---

**TABLE 2 | Comparison of genetic approaches.**

| Approach | Strengths | Limitations |
|----------|-----------|-------------|
| Genome-wide linkage analysis | ✓ Systemically scan the genome  
✓ Identify single gene with large effects | ✓ Requires hundreds of family members  
✓ Low resolution  
✓ Limited power for complex traits/diseases |
| Candidate gene association studies | ✓ Fine mapping  
✓ Focused interest of gene | ✓ Limited variants  
✓ Not powerful in gene discovery |
| Genome-wide association study | ✓ Hypothesis-free  
✓ Systemically scan the genome  
✓ Large variant coverage  
✓ Detection of common alleles  
✓ Powerful for complex traits/diseases | ✓ Expensive  
✓ Requires multiple tests  
✓ High false-negative rate  
✓ Usually fail to detect uncommon or rare variants |
| Phenome-wide association study | ✓ Detection of uncommon or rare variants  
✓ Re-discovery of known genes cross phenotypes  
✓ Association of a single allele to phenotypes | ✓ Definition of phenotype is ambiguous  
✓ Low phenotypic resolution |
| Whole genome sequencing | ✓ Systemically scan the genome  
✓ Detection of uncommon or rare variants  
✓ Detection of variants in non-coding regions | ✓ Expensive  
✓ Platform dependant |
| Animal models | ✓ Greater ability in environmental control  
✓ Fast breeding rates  
✓ Reproducible and easier access to trait-relevant tissues  
✓ Short life span  
✓ Genetic manipulations (gene-focused) | ✓ Can resemble gene-phenotype effects in human |
| The Collaborative Cross | ✓ Systemic scan within a defined RI family  
✓ Availability of hundreds of strains  
✓ Individual strains can be reproduced and used as mouse models | ✓ Expensive in breeding and maintaining lines |
| Mutagenesis | ✓ Create numerous mutants  
✓ Rich variety of alleles | ✓ Labor required  
✓ May don’t get desired mutants |

---
the customized guide DNAs that target bone genes such as osteocalcin (Lambert et al., 2016), and analyzing structural variations contributing to skeleton patterning in mice (Kraft et al., 2015; Lupianez et al., 2015). CRISPR/Cas9 may rapidly unveil the function of any newly identified osteoporosis susceptibility genes in bone and lead to effective treatment of this disease.

CONCLUSION AND FUTURE DIRECTIONS

Osteoporosis is a common but complex disorder, with only a few rare phenotypes inherited in a Mendelian pattern. Over the past two decades more than 220 genes have been associated with BMD or osteoporosis. However, less than 20% of BMD variation can be explained by those “confidently identified” genes. To identify the majority of the “missing” heritability requires further efforts in studies with larger populations across differing ethnicities, extensive application of current available genetic approaches, improvements in SNP coverage, and development of novel methods that can identify genotype-phenotype interaction in a fast, economic and precise way.

Each genetic approach has its strengths and limitations in discovering genes regulating bone mass (Table 2). Linkage analysis appears to have reached its limit in unveiling genes that can affect complex traits like BMD. Candidate gene association studies are useful in identifying the relationship between SNPs and traits within a suggested locus. GWAS, despite the huge breakthrough in its technique and application, only explains a small proportion of the total heritability of osteoporosis-related phenotypes, likely due in part to the large “false-negative” rate. It is realized that a GWAS provides more reliable results with a larger population size or combining published GWAS data via meta-analysis. In addition, it is worth mentioning that GWAS utilizing SNP array technology with subsequent genotype imputation tends to target common variants. As a novel genetic approach, PhEnOSS has been used as a complementary approach to GWAS in a reverse manner to identify variants associated with animal and/or human phenomes. It holds promise to discover uncommon or rare genetic variants which are usually missed by GWAS, despite that the application of PhEnOSS is still in its infancy. WGS also provides an alternative approach to exploring low-frequency variants or at all variants within a specific locus. With the dramatic reduction in cost, this approach allows the identification of more uncommon or rare variants and paves the way for personalized medicine. A combination of all these approaches with greater international collaboration allows researchers to identify more genes associated with complex diseases like osteoporosis. In addition, the majority of genes identified for BMD or osteoporosis are either rare mutations with large effects or common variants with small effects, focus should be shifted to searching for uncommon (1% ≤ MAF ≤ 5%) variants with modest effects. WGS appears to be more suitable than GWLA or GWAS to achieve this goal, if the cost of WGS becomes as low as one or two hundred United States dollars.

The CC and ENU mutagenesis mouse models offer another platform to identify genes responsible for osteoporosis and other complex diseases. The advantages provided by animal studies, including faster breeding, better control of environmental factors, and importantly, ease of genetic manipulation, make a strong case for their application in genetic research, although to date there are very few studies that have utilized CC mice and ENU mutagenesis. Genome editing tools, in particular CRISPR/Cas9, provide an effective way to dissect a gene that influences a specific trait or phenotype (e.g., BMD and osteoporosis), and direct therapies (e.g., gene therapy) to correct those defects induced by mutated or defective proteins. Given genome editing is in its infancy in guiding treatment of osteoporosis and other diseases, CRISPR/Cas9 appears to be a powerful tool in accelerating the CC mice screening process.

There is still much work to be done to fully characterize the genetic basis of osteoporosis. A greater understanding of the genetic variation underlying the development of peak bone mass, and rates of bone loss during aging, is required to develop strategies to optimize bone health in an aging population. Combining the available databases that link and characterize phenotypes provides us with an avenue to further investigate the mechanisms underlying the pathology. Moreover, osteoporosis is a complex condition which is influenced by a wide range of factors such as ethnicity, gender, age and environment. By far, most research focused on osteoporosis has been conducted in study populations of European origin. Further well-powered studies in other ethnic groups are necessary to provide a better picture of the correlation between the human genome and osteoporosis.

With the knowledge gained from varied sources, personalized or precision treatment may be ultimately offered to patients based on the advances in understanding their “unique” genome through various genetic approaches, in addition to environmental factors.

DATA AVAILABILITY

No datasets were generated for this study.

AUTHOR CONTRIBUTIONS

JY conducted the research and drafted the manuscript. JT, BM, and ZZ provided valuable opinions and assistance in the process of drafting and revision of the manuscript. JZ, GM, and JX supervised the study and revised the manuscript.

FUNDING

Partially supported by Guangxi Scientific Research and Technology Development Plan Project (GKAD17129012, GKG13349003, and 1598013-15), Western Australia Medical and Health Research Infrastructure Fund, Arthritis Australia Foundation, The University of Western Australia (UWA) Research Collaboration Awards, and the Australian Health and Medical Research Council (NHMRC, Nos. APP1107828, APP1027932, APP1127156, and APP1163933).
REFERENCES

Ackert-Bicknell, C. L., Karasik, D., Li, Q. A., Smith, R. V., Hsu, Y. H., Churchill, G. A., et al. (2010). Mouse BMD quantitative trait loci show improved concordance with human genome-wide association loci when recalculated on a new, common mouse genetic map. J. Bone Miner. Res. 25, 1808–1820. doi: 10.1002/jbmr.72

Adler, I. N., Stine, K. C., Kurtzburg, J., Kinder, D. L., Cox, K. S., Lensing, S. Y., et al. (2000). Dual-energy x-ray absorptiometry in osteoporosis. South. Med. J. 93, 501–503. doi: 10.1097/00007611-20000930-00013

Andrew, T., Antoniades, L., Scurrah, K. J., Macgregor, A. J., and Spector, T. D. (2005). Risk of wrist fracture in women is heritable and is influenced by genes that are largely independent of those influencing BMD. J. Bone Miner. Res. 20, 67–74. doi: 10.1359/JBMR.040105

Bazil, D., and Steiner, R. D. (2009). Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet. Med. 11, 375–385. doi: 10.1097/GIM.0b013e3181af7b7

Black, D. M., Cauley, J. A., Wagoner, R., Ensrud, K., Fink, H. A., Hillier, T. A., et al. (2016). Adler, I. N., Stine, K. C., Kurtzburg, J., Kinder, D. L., et al. (2012). Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice. G3 Genet. Med. 6, 111.001800

Burr, D. B. var(2002). Osteoporosis and fracture risk: bone matrix quality. J. Bone Miner. Res. 17, 213–221. doi: 10.1002/jbmr.1180

Cui, Z., Renfu, Q., and Jinfu, W. (2018). Development and application of nrg1521 gene for osteoporosis. Bone 1000806.

Estrada, K., Styrkarsdottir, U., Evangelou, E., Hsu, Y. H., Duncan, E. L., Ntzani, E. E., et al. (2012). Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491–501. doi: 10.1038/ng.2249

Ferguson, B., Ram, R., Handoko, H. Y., Mukhopadhyay, P., Muller, H. K., Soyer, H. P., et al. (2015). Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression. Oncogene 34, 2879–2886. doi: 10.1038/onc.2014.227

Guo, Y., Tan, L. J., Lei, S. F., Yang, T. L., Chen, X. D., Zhang, F., et al. (2010). Genome-wide association study identifies ALDH7A1 as a novel susceptibility gene for osteoporosis. PLoS Genet. 6:e1000806. doi: 10.1371/journal.pgen.1000806

Harris, N. L., Rattray, K. R., Tye, C. E., Underhill, T. M., Somerman, M. J., D’Errico, J. A., et al. (2000). Functional analysis of bone sialoprotein: identification of the hydroxyapatite-nucleating and cell-binding domains by recombimant peptide expression and site-directed mutagenesis. Bone 27, 795–802. doi: 10.1016/S8756-3282(00)00392-6

Hebbring, S. J. (2014). The challenges, advantages and future of phenome-wide association studies. Immunology 141, 157–165. doi: 10.1111/imm.12195

Hernandez-de Sosa, N., Athanasiadis, G., Malouf, J., Laiz, A., Marin, A., Herrera, S., et al. (2014). Heritability of bone mineral density in a multivariate family-based study. Calcif. Tissue Int. 94, 590–596. doi: 10.1007/s00223-014-9852-9

Hirschhorn, J. N., and Daly, M. J. (2005). Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6, 95–108. doi: 10.1038/nrg15121

Hoggart, C. J., Clark, T. G., De Iorio, M., Whittacker, J. C., and Balding, D. J. (2008). Genome-wide significance for dense SNP and resequencing data. Genet. Epidemiol. 32, 179–185. doi: 10.1007/epi.20292

Howard, G. M., Nguyen, T. V., Harris, M., Kelly, P. J., and Eisman, J. A. (1998). Genetic and environmental contributions to the association between quantitative ultrasound and bone mineral density measurements: a twin study. J. Bone Miner. Res. 13, 1318–1327. doi: 10.1359/jbmr.1998.13.8.1318

Hsu, Y. H., and Kiel, D. P. (2012). Clinical review: genome-wide association studies of skeletal phenotypes: what we have learned and where we are headed. J. Clin. Endocrinol. Metab. 97, E1958–E1977. doi: 10.1210/jc.2012-1890

Hsu, Y. H., Xu, X., Terweduwe, H. A., Niu, T., Hong, X., Wu, D., et al. (2007). Large-scale genome-wide linkage analysis for loci linked to BMD at different skeletal sites in extreme selected sibships. J. Bone Miner. Res. 22, 184–194. doi: 10.1359/jbmr.061015

Hsu, Y. H., Zillikens, M. C., Wilson, S. G., Faber, C. R., Demissie, S., Soranzo, N., et al. (2010). An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility Loci for osteoporosis-related traits. PLoS Genet. 6:e1000977. doi: 10.1371/journal.pgen.1000977

Ioannidis, J. P., Ng, M. Y., Sham, P. C., Zintzaras, E., Lewis, C. M., Deng, H. W., et al. (2007). Meta-analysis of genome-wide scans provides evidence for sex- and site-specific regulation of bone mass. J. Bone Miner. Res. 22, 173–183. doi: 10.1359/jbmr.060806

Ishimori, N., Li, R. H., Walsh, K. A., Korstanje, R., Rollins, J. A., Petkov, P., et al. (2006). Quantitative trait loci that determine BMD in C57BL/6J and 129S1/SvlmJ inbred mice. J. Bone Miner. Res. 21, 105–112. doi: 10.1359/JBMR.050902

Jadhav, G., Teguh, D., Kenny, J., Tickner, J., and Xu, J. (2016). Morc3 mutant mice exhibit reduced cortical area and thickness, accompanied by altered haematopoietic stem cells niche and bone cell differentiation. Sci. Rep. 6:25964. doi: 10.1038/srep25964

Jee, W. S., and Yao, W. (2001). Overview: animal models of osteopenia and osteoporosis. J. Musculoskelet Neuronal Interact. 1, 193–207.

Jepsen, K. J., Courtland, H. W., and Nadeau, J. H. (2010). Genetically determined phenotype covariation networks control bone strength. J. Bone Miner. Res. 25, 1581–1593. doi: 10.1002/jbmr.41

Jong, I. K., and Sander, J. D. (2013). TALENs: a widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 14, 49–55. doi: 10.1038/nrm3646

Karasis, D., Dupuis, J., Cho, K., Cupples, L. A., Zhou, Y., Kiel, D. P., et al. (2010). Refined QTLs of osteoporosis-related traits by linkage analysis with genome-wide SNPs: Framingham SHARE. Bone 46, 1114–1121. doi: 10.1016/j.bone.2010.01.001
Morahan, G., Balmer, L., and Monley, D. (2008). Establishment of "The Gene Mine": a resource for rapid identification of complex trait genes. Mamm. Genome 19, 390–393. doi: 10.1007/s00335-008-9134-9

Mullin, B. H., Hua Zhao, J., Brown, S. J., Perry, J. R. B., Luan, J., Zheng, H. F., et al. (2017). Genome-wide association study meta-analysis for quantitative ultrasound parameters of bone identifies five novel loci for broadband ultrasound attenuation. Hum. Mol. Genet. 26, 2791–2802. doi: 10.1093/hmg/ddx174

Mullin, B. H., Walsh, J. P., Zheng, H. F., Brown, S. J., Surdulescu, G. L., Curtis, C., et al. (2016). Genome-wide association study using family-based cohorts identifies the WLS and CCDC170/ESRI1 loci as associated with bone mineral density. BMC Genomics 17:136. doi: 10.1186/s12864-016-2481-0

Mullin, B. H., Zhu, K., Brown, S. J., Mullin, S., Tickner, J., Pavlos, N. J., et al. (2019). Genetic regulatory mechanisms in human osteoclasts suggest a role for the STMP1 and DCSTAMP genes in Paget's disease of bone. Sci. Rep. 9:1052. doi: 10.1038/s41598-018-3769-9

Mullin, B. H., Zhu, K., Xu, J., Brown, S. J., Mullin, S., Tickner, J., et al. (2018). Expression quantitative trait locus study of bone mineral density GWAS variants in human osteoclasts. J. Bone Miner. Res. 33, 1044-1051. doi:10.1002/jbmr.3412

Nelms, K. A., and Goodnow, C. C. (2001). Genome-wide ENU mutagenesis to reveal immune regulators. Immunity 15, 409–418. doi: 10.1016/S1074-7613(01)00199-6

Park, J. H., Song, Y. M., Sung, J., Lee, K., Kim, Y. S., and Park, Y. S. (2012). Genetic influence on bone mineral density in Korean twins and families: the healthy twin study. Osteoporos. Int. 23, 1343–1349. doi: 10.1007/s00198-011-1685-z

Paterson, L., Lorentzon, M., Lehtimaki, T., Eriksson, J., Kahonen, M., Raitakari, O., et al. (2013). Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. PLoS Genet. 9:e1003247. doi: 10.1371/journal.pgen.1003247

Patnala, R., Clements, J., and Batra, J. (2013). Candidate gene association studies: a comprehensive guide to useful in silicon tools. BMC Genet. 14:39. doi: 10.1186/1471-2156-14-39

Peltonen, L., and McKusick, V. A. (2001). Genomics and medicine. Dissecting human disease in the postgenomic era. Science 291, 1224–1229. doi: 10.1126/science.291.5507.1224

Phillippi, J., Xie, Y., Miller, D. R., Bell, T. A., Zhang, Z., Lenarcic, A. B., et al. (2014). Using the emerging Collaborative Cross to probe the immune system. Genes Immun. 15, 38–46. doi: 10.1038/gene.2013.59

Quail, M. A., Smith, M., Coupland, P., Otto, T. D., Harris, S. R., Connor, T. R., et al. (2012). A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 13:341. doi: 10.1186/1471-2164-13-341

Ralston, S. H. (2010). Genetics of osteoporosis. Ann. N. Y. Acad. Sci. 1192, 181–189. doi: 10.1196/annals.1648568

Ralston, S. H., Galwey, N., MacKay, I., Albagha, O. M., Cardon, L., Compston, J. E., et al. (2005). Loci for regulation of bone mineral density in men and women identified by genome wide linkage scan: the FAMOS study. Hum. Mol. Genet. 14, 935–961. doi: 10.1093/hmg/ddh088

Ram, R., Mehta, M., Balmer, L., Gatti, D. M., and Morahan, G. (2014). Rapid identification of major-effect genes using the collaborative cross. Genetics 198, 75–86. doi: 10.1534/genetics.113.160014

Ram, R., and Morahan, G. (2017). Complex trait analyses of the collaborative cross: tools and databases. Syst. Genet. Methods Protoc. 1488, 121–129. doi: 10.1007/978-1-4939-6427-7_5

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308. doi: 10.1038/nprot.2013.143

Richards, J. B., Kavvoura, F. K., Rivadeneira, F., Styrkarsdottir, U., Estrada, K., Raitakari, O., et al. (2010). Genome-wide association study of bone mineral density and fracture risk in normal variation in bone mineral density: the Framingham study. J. Bone Miner. Res. 25, 104–110. doi: 10.1002/jbmr.2304

Ritalahti, K., Peltonen, L., and McKusick, V. A. (2001). Genomics and medicine. Dissecting human disease in the postgenomic era. Science 291, 1224–1229. doi: 10.1126/science.291.5507.1224

Ritchie, M. D., Pinder, E. L., Bushing, N. B., Li, Y., Drennan, P. C., and Fidock, D. A. (2012). Deletions, inversions, duplications: engineering of structural variants using CRISPR/Cas9 technology. Dis. Model. Mech. 9, 1169–1179. doi: 10.1242/dmm.025247

Rizzic, I., Perugia, C., and Testi, M. (2009). Use of next generation sequencing to annotate the human genome. Hum. Genom. 1, 43, 1–10. doi: 10.1186/1471-2350-8-S1-S14

Rivera-Márquez, A., Yeo, S., van der Jeugd, H. P., de Vries, L. J., van Ommen, G. J., and Pellegri, A. M. (2010). Genetic regulatory mechanisms in human osteoclasts suggest a role for the STMP1 and DCSTAMP genes in Paget's disease of bone. Sci. Rep. 9:1052. doi: 10.1038/s41598-018-3769-9

Rikhotso, E., Reyneke, J. P., and Ferretti, C. (2008). Osteopetrosis: literature review and report of three cases. SADJ 63, 302–307.
Rivadeneira, F., Styrkarsdottir, U., Estrada, K., Halldorsson, B. V., Hsu, Y. H., Richards, J. B., et al. (2009). Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. *Nat. Genet.* 41, 1199–1206. doi: 10.1038/ng.446

Sebastian, A., and Loots, G. G. (2017). Genetics of Sost/SOST in sclerosteosis and van buchem disease animal models. *Metabolism* 80, 38–47. doi: 10.1016/j.metabol.2017.10.005

Shen, H., Zhang, Y. Y., Long, J. R., Xu, F. H., Liu, Y. Z., Xiao, P., et al. (2004). A genome-wide linkage scan for bone mineral density in an extended sample: evidence for linkage on 11q23 and Xq27. *J. Med. Genet.* 41, 743–751. doi: 10.1136/jmg.2004.020396

Shmookler Reis, R. J., and Ebert, R. H. II (2003). Animal models for discovery and assessment of genetic determinants of osteoporosis. *Osteoporos. Int.* 14(Suppl. 5), S100–S106.

Smith, L. M., Bigelow, E. M. R., Nolan, B. T., Faillace, M. E., Nadeau, J. H., Shmookler Reis, R. J., and Ebert, R. H. II (2003). Animal models for discovery and assessment of genetic determinants of osteoporosis. *Osteoporos. Int.* 14(Suppl. 5), S100–S106.

Tian, J., Liu, Q., Dong, S., Qiao, X., and Ni, J. (2010). A new method for multi-site-directed mutagenesis. *Anal. Biochem.* 406, 83–85. doi: 10.1016/j.ab.2010.06.018

Timpson, N. J., Tobias, J. H., Richards, J. B., Soranzo, N., Duncan, E. L., Sims, A. M., et al. (2009). Common variants in the region around Osterix are associated with bone mineral density and growth in childhood. *Hum. Mol. Genet.* 18, 1510–1517. doi: 10.1093/hmg/ddp052

Unnanuntana, A., Gladnick, B. P., Donnelly, E., and Lane, J. M. (2010). The assessment of fracture risk. *J. Bone Joint Surg. Am.* 92, 743–753. doi: 10.2106/JBJS.I.00919

Valdar, W., Flint, J., and Mott, R. (2006). Simulating the collaborative cross: power of quantitative trait loci detection and mapping resolution in large sets of recombinant inbred strains of mice. *Genetics* 172, 1783–1797. doi: 10.1534/genetics.104.039313

Wade, M. J. (2001). Epistasis, complex traits, and mapping genes. *Genetica* 112–113, 59–69. doi: 10.1023/A:1013316611768

Wang, X. S., Pandey, A. K., Mulligan, M. K., Williams, E. G., Mozhui, K., Li, Z. S., et al. (2016). Joint mouse-human phenotype-association to test gene function and disease risk. *Nat. Commun.* 7:10464. doi: 10.1038/ncomms10464

Wellcome Trust Case Control Consortium (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447, 661–678.

Wilkening, S., Chen, B. W., Bermejo, J. L., and Canzian, F. (2009). Is there still a need for candidate gene approaches in the era of genome-wide association studies? *Genomics* 93, 415–419. doi: 10.1016/j.ygeno.2008.12.011

Williams, B. O., and Warman, M. L. (2017). CRISPR/CAS9 technologies. *J. Bone Miner. Res.* 32, 883–888. doi: 10.1002/jbmr.3086

Xiong, D. H., Liu, X. G., Guo, Y. F., Tan, L. J., Wang, L., Sha, B. Y., et al. (2009). Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups. *Am. J. Hum. Genet.* 84, 388–398. doi: 10.1016/j.ajhg.2009.01.025

Xiong, Q., Qiao, Y., Hasty, K. A., Canale, S. T., Stuart, J. M., Beamer, W. G., et al. (2009). Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse. *Genomics* 93, 401–414. doi: 10.1016/j.ygeno.2008.12.008

Zhai, G., Andrew, T., Kato, B. S., Blake, G. M., and Spector, T. D. (2009). Genetic and environmental determinants on bone loss in postmenopausal Caucasian women: a 14-year longitudinal twin study. *Osteoporos. Int.* 20, 949–953. doi: 10.1007/s00198-008-0751-7

Zhang, L., Choi, H. J., Estrada, K., Lee, P. J., Li, J., Pei, Y. F., et al. (2014). Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. *Hum. Mol. Genet.* 23, 1923–1933. doi: 10.1093/hmg/ddt575

Zheng, H. F., Forgetta, V., Hsu, Y. H., Estrada, K., Rosello-Diez, A., Leo, P. J., et al. (2015). Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. *Nature* 526, 112–117. doi: 10.1038/nature14878

Zheng, H. F., Tobias, J. H., Duncan, E., Evans, D. M., Eriksson, J., Paternoster, L., et al. (2012). WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. *PLoS Genet.* 8:e1002745. doi: 10.1371/journal.pgen.1002745

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Yuan, Tickner, Mallin, Zhao, Zeng, Morahan and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.